Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Vasquez, Elisardo C ^a,b   Peotta, Veronica A ^c   Gava, Agata L ^a   Pereira, Thiago M C ^d   Meyrelles, Silvana S ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria   (Brazil)

^c UNIVERSITY OF IOWA   (United States)

^d Federal Institute of Education   (Brazil)

Author keywords

atherosclerosis; cardiac function; Hypercholesterolemia; mouse; vascular senescence

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN[1-7]; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TETRAHYDROCANNABINOL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AGING; AORTA; ARTERIAL PRESSURE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD FLOW VELOCITY; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CELL DEATH; CELL REGENERATION; CELL THERAPY; CIRCADIAN RHYTHM; CORONARY ARTERY; CYTOKINE RELEASE; DIAPEDESIS; DIET; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FOAM CELL; GENE TRANSFER; HEART RATE VARIABILITY; HEART VENTRICLE HYPERTROPHY; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; LIPID OXIDATION; LIPID PEROXIDATION; LYSOSOME; MONOCYTE; MONONUCLEAR CELL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STEM CELL; TUNICA MEDIA; VASCULAR ENDOTHELIUM; WESTERN DIET; ANIMAL; BLOOD VESSEL; DISEASE MODEL; GENETICS; HEART; HEMODYNAMICS; HYPERLIPOPROTEINEMIA TYPE 3; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALIA;

AGING; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD VESSELS; DIET; DISEASE MODELS, ANIMAL; HEART; HEMODYNAMICS; HYPERLIPOPROTEINEMIA TYPE III; MICE; NITRIC OXIDE; REACTIVE OXYGEN SPECIES;

EID: 84856770907     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-22     Document Type: Review

References (94)

1. Methods employed for induction and analysis of experimental myocardial infarction in mice. Borst O, Ochmann C, Schönberger T, Jacoby C, Stellos K, Seizer P, Flögel U, Lang F, Gawaz M, Cell Physiol Biochem 2011 28 1 12 10.1159/000331708 21865843
2. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL, Cell 1992 71 2 343 53 10.1016/0092-8674(92)90362-G 1423598
3. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N, Proc Natl Acad Sci USA 1992 89 10 4471 5 10.1073/pnas.89.10.4471 1584779
4. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. Zhang SH, Reddick RL, Burkey B, Maeda N, J Clin Invest 1994 94 3 937 45 10.1172/JCI117460 8083379 (Pubitemid 24286433)
5. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ, Proc Natl Acad Sci USA 1996 93 19 10022 7 10.1073/pnas.93.19.10022 8816744 (Pubitemid 26314567)
6. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Bonthu S, Heistad DD, Chappell DA, Lamping KG, Faraci FM, Arterioscler Thromb Vasc Biol 1997 17 11 2333 40 10.1161/01.ATV.17.11.2333 9409199 (Pubitemid 28015965)
7. Chronic ET(A) receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. d'Uscio LV, Barton M, Shaw S, Lüscher TF, Cardiovasc Res 2002 53 2 487 95 10.1016/S0008-6363(01)00469-2 11827700 (Pubitemid 34117700)
8. Sex as a profound modifier of atherosclerotic lesion development in apolipoprotein E-deficient mice with different genetic backgrounds. Surra JC, Guillén N, Arbonés-Mainar JM, Barranquero C, Navarro MA, Arnal C, Orman I, Segovia JC, Osada J, J Atheroscler Thromb 2010 17 7 712 21 10.5551/jat.3541 20460831
9. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R, Arterioscler Thromb 1994 14 1 133 40 10.1161/01.ATV.14.1.133 8274468
10. Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice. Jiang F, Gibson AP, Dusting GJ, Eur J Pharmacol 2001 424 2 141 9 10.1016/S0014- 2999(01)01140-2 11476760 (Pubitemid 32718618)
11. The pathogenesis of atherosclerosis: a perspective for the 1990s. Ross R, Nature 1993 362 801 9 10.1038/362801a0 8479518 (Pubitemid 23132154)
12. Inflammation, atherosclerosis, and coronary artery disease. Hansson GK, N Engl J Med 2005 352 1685 95 10.1056/NEJMra043430 15843671 (Pubitemid 40530235)
13. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stoll G, Bendszus M, Stroke 2006 37 7 1923 32 10.1161/01.STR.0000226901.34927.10 16741184 (Pubitemid 44297753)
14. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Negre-Salvayre A, Coatrieux C, Ingueneau C, Salvayre R, Br J Pharmacol 2008 153 1 6 20 10.1038/sj.bjp.0707395 17643134
15. Overview of murine atherosclerosis series. Getz GS, Curr Drug Targets 2007 8 1144 49 10.2174/138945007782403865 18045092 (Pubitemid 350238915)
16. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Weber C, Zernecke A, Libby P, Nat Rev Immunol 2008 8 802 15 10.1038/nri2415 18825131
17. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Steinberg D, Nat Med 2002 8 1211 7 10.1038/nm1102-1211 12411947 (Pubitemid 35373551)
18. New insights into immunological aspects of atherosclerosis. Jawie J, Pol Arch Med Wewn 2008 118 3 127 31 18476459
19. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice. Shemesh S, Kamari Y, Shaish A, Olteanu S, Kandel-Kfir M, Almog T, Grosskopf I, Apte RN, Harats D, Atherosclerosis 2012
20. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Zhou X, Nicoletti A, Elhage R, Hansson GK, Circulation 2000 102 2919 22 11113040
21. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R, Arterioscler Thromb 1994 14 1 133 40 10.1161/01.ATV.14.1.133 8274468
22. A mouse model for human atherosclerosis: long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice. Coleman R, Hayek T, Keidar S, Aviram M, Acta Histochem 2006 108 6 415 24 10.1016/j.acthis.2006.07.002 17007910 (Pubitemid 44708294)
23. Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC, Lipids Health Dis 2011 10 211 10.1186/1476-511X-10-211 22082357
24. Plaque-associated endothelial dysfunction in apolipoprotein E-deficient mice on a regular diet. Effect of human apolipoprotein AI. Crauwels HM, Van Hove CE, Holvoet P, Herman AG, Bult H, Cardiovasc Res 2003 59 1 189 99 10.1016/S0008-6363(03)00353-5 12829190 (Pubitemid 36776385)
25. -/- mice. Johansson ME, Hägg U, Wikström J, Wickman A, Bergström G, Gan LM, Clin Sci (Lond) 2005 108 6 531 8 10.1042/CS20040322 (Pubitemid 40827561)
26. Impairment of endothelium-dependent arterial relaxation by high-fat feeding in ApoE-deficient mice: toward normalization by human ApoA-I expression. Deckert V, Lizard G, Duverger N, Athias A, Palleau V, Emmanuel F, Moisant M, Gambert P, Lallemant C, Lagrost L, Circulation 1999 100 11 1230 5 10484545 (Pubitemid 29426600)
27. Decreased sensitivity to nitric oxide in the aorta of severely hypercholesterolemic apolipoprotein E-deficient mice. Yaghoubi M, Oliver-Krasinski J, Cayatte AJ, Cohen RA, J Cardiovasc Pharmacol 2000 36 6 751 7 10.1097/00005344-200012000-00010 11117375
28. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. d'Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC, Katusic ZS, Arterioscler Thromb Vasc Biol 2001 21 6 1017 22 10.1161/01.ATV.21.6.1017 11397713 (Pubitemid 34168662)
29. Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E-deficient mice with pre-existing atherosclerosis. Guns PJ, Van Assche T, Verreth W, Fransen P, Mackness B, Mackness M, Holvoet P, Bult H, Br J Pharmacol 2008 153 3 508 16 10.1038/sj.bjp.0707585 18059326 (Pubitemid 351199014)
30. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG, Circulation 2001 103 9 1282 8 11238274 (Pubitemid 32221353)
31. Areceptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Münter K, Lüscher TF, Proc Natl Acad Sci USA 1998 95 24 14367 72 10.1073/pnas.95.24.14367 9826706 (Pubitemid 28549373)
32. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Wassmann S, Czech T, van Eickels M, Fleming I, Böhm M, Nickenig G, Circulation 2004 110 19 3062 7 10.1161/01.CIR.0000137970.47771.AF 15277329 (Pubitemid 39491999)
33. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Weiss D, Kools JJ, Taylor WR, Circulation 2001 103 3 448 54 11157699 (Pubitemid 32105987)
34. Endothelial dysfunction of resistance vessels in female apolipoprotein E-deficient mice. Cola MS, Gava AL, Meyrelles SS, Vasquez EC, Lipids Health Dis 2010 9 51 10.1186/1476-511X-9-51 20482882
35. Cerebral vascular dysfunction during hypercholesterolemia. Kitayama J, Faraci FM, Lentz SR, Heistad DD, Stroke 2007 38 7 2136 41 10.1161/STROKEAHA.107. 481879 17525390 (Pubitemid 47012280)
36. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Tabas I, Williams KJ, Boren J, Circulation 2007 116 1832 44 10.1161/CIRCULATIONAHA.106.676890 17938300 (Pubitemid 350287108)
37. Progress and challenges in translating the biology of atherosclerosis. Libby P, Ridker PM, Hansson GK, Nature 2011 473 317 25 10.1038/nature10146 21593864
38. Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport. Williams KJ, Scalia R, Mazany KD, Rodrigueza WV, Lefer AM, Arterioscler Thromb Vasc Biol 2000 20 4 1033 9 10.1161/01.ATV.20.4.1033 10764669 (Pubitemid 30207578)
39. Impaired carotid occlusion reflex in apoE deficient mice and its reversal by gene transfer to carotid sinus. Meyrelles SS, Chapleau MW, J Hypertens 2000 18 Suppl 4 202
40. Fluvastatin prevents renal dysfunction and vascular NO deficit in apolipoprotein E-deficient mice. Gervais M, Pons S, Nicoletti A, Cosson C, Giudicelli JF, Richer C, Arterioscler Thromb Vasc Biol 2003 23 2 183 9 10.1161/01.ATV.0000051404.84665.49 12588757 (Pubitemid 36231926)
41. Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Arruda RM, Peotta VA, Meyrelles SS, Vasquez EC, Hypertension 2005 46 4 932 6 10.1161/01.HYP.0000182154.61862.52 16087779
42. Evaluation of aortic remodeling in apolipoprotein E-deficient mice and renovascular hypertensive mice. Nogueira BV, Peotta VA, Meyrelles SS, Vasquez EC, Arch Med Res 2007 38 8 816 21 10.1016/j.arcmed.2007.06.005 17923260 (Pubitemid 47513267)
43. Altered mechanisms of endothelium-dependent dilation in skeletal muscle arterioles with genetic hypercholesterolemia. Stapleton PA, Goodwill AG, James ME, Frisbee JC, Am J Physiol Regul Integr Comp Physiol 2007 293 3 1110 9 10.1152/ajpregu.00410.2007 17626122 (Pubitemid 47358931)
44. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U, Circulation 2008 117 18 2377 87 10.1161/CIRCULATIONAHA.107.746537 18443241 (Pubitemid 351653554)
45. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE, Arterioscler Thromb Vasc Biol 2010 30 8 1606 13 10.1161/ATVBAHA.110. 204453 20448208
46. Hypertension and endothelial dysfunction in apolipoprotein E knockout mice. Yang R, Powell-Braxton L, Ogaoawara AK, Dybdal N, Bunting S, Ohneda O, Jin H, Arterioscler Thromb Vasc Biol 1999 19 11 2762 8 10.1161/01.ATV.19.11.2762 10559023 (Pubitemid 29536055)
47. -/- mice in vivo. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL, Circulation 2003 107 19 2480 6 10.1161/01.CIR.0000065601.83526.3E 12719275 (Pubitemid 36605232)
48. Atherosclerosis and arterial blood pressure in mice. Lu H, Cassis LA, Daugherty A, Curr Drug Targets 2007 8 11 181 9
49. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Daugherty A, Manning MW, Cassis LA, Br J Pharmacol 2001 134 4 865 70 10.1038/sj.bjp.0704331 11606327 (Pubitemid 33016158)
50. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA, J Clin Invest 2003 112 9 1318 31 14597759 (Pubitemid 38057686)
51. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Ferrario CM, Smith R, Levy P, Strawn W, Am J Med Sci 2002 323 1 17 24 10.1097/00000441-200201000-00004 11814137 (Pubitemid 34650117)
52. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA, Circulation 2004 110 25 3849 57 10.1161/01.CIR.0000150540.54220.C4 15596561 (Pubitemid 40023984)
53. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. Daugherty A, Manning MW, Cassis LA, J Clin Invest 2000 105 1605 12 10.1172/JCI7818 10841519 (Pubitemid 30390311)
54. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Vinh A, Widdop RE, Drummond GR, Gaspari TA, Cardiovasc Res 2008 77 1 178 87 18006471 (Pubitemid 351195149)
55. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, Ichikawa I, Fazio S, Kon V, Atherosclerosis 2006 184 2 312 21 10.1016/j.atherosclerosis.2005.05.016 16023123 (Pubitemid 43049715)
56. Angiotensin II amplifies macrophage-driven atherosclerosis. Nobuhiko A, Suganuma E, Babaev VR, Fogo A, Swift LL, Linton MF, Fazio S, Ichikawa I, Kon V, Arterioscler Thromb Vasc Biol 2004 24 11 2143 8 10.1161/01.ATV.0000145607.03879. e0 15374850 (Pubitemid 39482443)
57. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Cheng XW, Song H, Sasaki T, Hu L, Inoue A, Bando YK, Shi GP, Kuzuya M, Okumura K, Murohara T, Hypertension 2011 57 5 981 9 10.1161/HYPERTENSIONAHA.110.168385 21464389
58. Differential effects of angiotensin II on atherogenesis at the aortic sinus and descending aorta of apolipoprotein E-deficient mice. Zhou Y, Chen R, Catanzaro SE, Hu L, Dansky HM, Catanzaro DF, Am J Hypertens 2005 18 4 Pt 1 486 92 15831357
59. Peripheral vascular stenosis in apolipoprotein E-deficient mice: potential roles of lipid deposition, medial atrophy, and adventitial inflammation. Seo HS, Lombardi DM, Polinsky P, Powell-Braxton L, Bunting S, Schwartz SM, Rosenfeld ME, Arterioscler Thromb Vasc Biol 1997 17 3593 3601 10.1161/01.ATV.17.12.3593 9437210 (Pubitemid 28028573)
60. A novel 3-dimensional micro-ultrasound approach to automated measurement of carotid arterial plaque volume as a biomarker for experimental atherosclerosis. Walker M, Campbell BR, Azer K, Tong C, Fang K, Cook JJ, Forrest MJ, Kempadoo K, Wright SD, Saltzman JS, MacIntyre E, Hargreaves R, Atherosclerosis 2009 204 1 55 65 10.1016/j.atherosclerosis.2008.09.013 19135672
61. Cardiac and vascular changes in elderly atherosclerotic mice: the influence of gender. Pereira TM, Nogueira BV, Lima LC, Porto ML, Arruda JA, Vasquez EC, Meyrelles SS, Lipids Health Dis 2010 9 87 10.1186/1476-511X-9-87 20723257
62. Expansive remodeling is a response of the plaque-related vessel wall in aortic roots of ApoE-deficient mice: an experiment of nature. Bentzon JF, Pasterkamp G, Falk E, Arterioscler Thromb Vasc Biol 2003 23 257 62 10.1161/01.ATV.0000051387.70962.79 12588768 (Pubitemid 36231937)
63. Mononuclear cell therapy attenuates atherosclerosis in apoE KO mice. Porto ML, Lima LC, Pereira TM, Nogueira BV, Tonini CL, Campagnaro BP, Meyrelles SS, Vasquez EC, Lipids Health Dis 2011 10 155 10.1186/1476-511X-10-155 21896159
64. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention- Pashkow FJ, Int J Inflam 2011 2011 514623 21860805
65. Vascular cell senescence: contribution to atherosclerosis. Minamino T, Komuro I, Circ Res 2007 100 1 15 26 10.1161/01.RES.0000256837.40544.4a 17204661 (Pubitemid 46074968)
66. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S, Stadtman ER, Arch Biochem Biophys 1995 324 241 8 10.1006/abbi.1995.0036 8554315 (Pubitemid 26006406)
67. Aging and genome maintenance: lessons from the mouse- Hasty P, Campisi J, Hoeijmakers J, van Steeg H, Vijg J, Science 2003 299 1355 9 10.1126/science.1079161 12610296 (Pubitemid 36254641)
68. SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis. Ota H, Eto M, Ogawa S, Iijima K, Akishita M, Ouchi Y, J Atheroscler Thromb 2010 17 5 431 5 10.5551/jat.3525 20215708
69. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I, Circulation 2002 105 13 1541 4 10.1161/01.CIR.0000013836.85741.17 11927518 (Pubitemid 34297628)
70. eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Tsao PS, Circ Res 2001 89 9 793 8 10.1161/hh2101.098443 11679409 (Pubitemid 34633850)
71. Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress. Hans CP, Feng Y, Naura AS, Zerfaoui M, Rezk BM, Xia H, Kaye AD, Matrougui K, Lazartigues E, Boulares AH, PLoS One 2009 4 10 7430 10.1371/journal.pone.0007430 19823587
72. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Martinet W, Knaapen MW, De Meyer GR, Herman AG, Kockx MM, Circulation 2002 106 8 927 32 10.1161/01.CIR.0000026393.47805.21 12186795 (Pubitemid 34925325)
73. PARP1 is required for adhesion molecule expression in atherogenesis. von Lukowicz T, Hassa PO, Lohmann C, Borén J, Braunersreuther V, Mach F, Odermatt B, Gersbach M, Camici GG, Stähli BE, Tanner FC, Hottiger MO, Lüscher TF, Matter CM, Cardiovasc Res 2008 78 1 158 66 10.1093/cvr/cvm110 18093987 (Pubitemid 351430953)
74. Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging. Pacher P, Mabley JG, Soriano FG, Liaudet L, Szabá C, Int J Mol Med 2002 9 6 659 64 12011985
75. Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. Benkö R, Pacher P, Vaslin A, Kollai M, Szabá C, Life Sci 2004 75 10 1255 61 10.1016/j.lfs.2004.04.007 15219813 (Pubitemid 38829350)
76. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F, Nature 2005 434 782 6 10.1038/nature03389 15815632 (Pubitemid 44739523)
77. N-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein E-deficient mice by reducing superoxide production. Shimada K, Murayama T, Yokode M, Kita T, Uzui H, Ueda T, Lee JD, Kishimoto C, Circ J 2009 73 7 1337 41 10.1253/circj.CJ-08-1148 19436121
78. The impact of progenitor cells in atherosclerosis. Xu Q, Nat Clin Pract Cardiovasc Med 2006 3 2 94 101 10.1038/ncpcardio0396 16446778 (Pubitemid 43203378)
79. Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Wassmann S, Werner N, Czech T, Nickenig G, Circ Res 2006 99 8 74 83 10.1161/01.RES.0000246095.90247.d4 16990568 (Pubitemid 44556373)
80. Hemodynamic changes in apolipoprotein E-knockout mice. Hartley CJ, Reddy AK, Madala S, Martin-McNulty B, Vergona R, Sullivan ME, Halks-Miller M, Taffet GE, Michael LH, Entman ML, Wang YX, Am J Physiol Heart Circ Physiol 2000 279 5 2326 34 11045969
81. Evaluation of baroreflex control of heart rate in renovascular hypertensive mice. Peotta VA, Gava AL, Vasquez EC, Meyrelles SS, Can J Physiol Pharmacol 2007 85 8 761 6 10.1139/Y07-067 17901885 (Pubitemid 350144735)
82. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM, Rosenberg RD, Schrenzel M, Krieger M, Circ Res 2002 90 3 270 6 10.1161/hh0302.104462 11861414 (Pubitemid 34633927)
83. Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E. Wu JH, Hagaman J, Kim S, Reddick RL, Maeda N, Arterioscler Thromb Vasc Biol 2002 22 3 469 75 10.1161/hq0302. 105287 11884292 (Pubitemid 34218756)
84. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL, Circulation 2001 104 4 448 54 10.1161/hc2901.091399 11468208 (Pubitemid 32678276)
85. Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice. Wang YX, Neurobiol Aging 2005 26 3 309 16 10.1016/j.neurobiolaging.2004.06.018 15639308 (Pubitemid 40082713)
86. Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR and expression and reducing TC, MMP-9, and Cat S levels. Qin YW, Ye P, He JQ, Sheng L, Wang LY, Du J, Acta Pharmacol Sin 2010 31 10 1350 8 10.1038/aps.2010.109 20835264
87. Myocardial infarction following atherosclerosis in murine models. Braun A, Rigotti A, Trigatti BL, Curr Drug Targets 2008 9 3 217 23 10.2174/138945008783755566 18336240 (Pubitemid 351843603)
88. Cardiac fibrosis and diastolic dysfunction after myocardial infarction in apolipoprotein E knockout mice. French CJ, Zaman AK, Sobel BE, Coron Artery Dis 2009 20 7 479 82 10.1097/MCA.0b013e3283319b6c 19770640
89. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, Palinski W, J Pathol 2001 195 2 257 63 10.1002/path.915 11592107 (Pubitemid 32899037)
90. In vivo echocardiographic detection of cardiovascular lesions in apolipoprotein E-knockout mice using a novel high-frequency high-speed echocardiography technique. Onozuka H, Fujii S, Mikami T, Yamada S, Ishimori N, Shimizu T, Furumoto T, Nakai Y, Komuro K, Nishihara K, Okamoto H, Kitabatake A, Circ J 2002 66 3 272 6 10.1253/circj.66.272 11922277 (Pubitemid 34462414)
91. Increased aortic stiffness assessed by pulse wave velocity in apolipoprotein E-deficient mice. Wang YX, Halks-Miller M, Vergona R, Sullivan ME, Fitch R, Mallari C, Martin-McNulty B, da Cunha V, Freay A, Rubanyi GM, Kauser K, Am J Physiol Heart Circ Physiol 2000 278 2 428 34 10666072
92. Reduced cardiac functional reserve in apolipoprotein E knockout mice. Vincelette J, Martin-McNulty B, Vergona R, Sullivan ME, Wang YX, Transl Res 2006 148 1 30 6 10.1016/j.lab.2006.03.007 16887496 (Pubitemid 44302097)
93. Animal models of cardiovascular diseases. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A, Egido J, J Biomed Biotechnol 2011 2011 497841 21403831
94. + mice with hypercholesterolemia, hypertension, and decreased baroreflex sensitivity spontaneously develop heart failure with age. Sabharwal R, Weiss RM, Stauss HM, Sigmund CD, Abboud FM, Chapleau MW, FASEB J 2007 21 753.14